RELATIONSHIP OF URINARY PSEUDOURIDINE AND 1-METHYLADENOSINE TO ACTIVITY OF LEUKEMIA AND LYMPHOMA

被引:56
作者
ITOH, K
KONNO, T
SASAKI, T
ISHIWATA, S
ISHIDA, N
MISUGAKI, M
机构
[1] TOHOKU UNIV HOSP, DEPT PHARMACEUT SCI, 1-1 SEIRYO MACHI, AOBA KU, SENDAI 980, JAPAN
[2] TOHOKU UNIV, TB & CANC RES INST, DEPT PEDIAT, SENDAI, MIYAGI 980, JAPAN
[3] TOHOKU UNIV, SCH MED, DEPT INTERNAL MED 2, SENDAI, MIYAGI 980, JAPAN
[4] SENDAI INST MICROBIOL, SENDAI, JAPAN
关键词
URINARY MODIFIED NUCLEOSIDES; PSEUDOURIDINE; 1-METHYLADENOSINE; INHIBITION ELISA; LEUKEMIA AND LYMPHOMA;
D O I
10.1016/0009-8981(92)90087-7
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Urinary levels of pseudouridine and 1-methyladenosine in patients with leukemia and lymphoma were measured by the inhibition ELISA using monoclonal antibodies to determine the correlation of nucleosides excretion with disease activity. Significantly elevated levels of these nucleosides were detected in patients with all types of disease tested. Seventy-seven percent (46/60) and 62% (37/6) of patients had elevated levels of pseudouridine and 1-methyladenosine above normal mean + 2S.D., respectively, and combination assay of these nucleosides gave higher positive rate (87%; 52/60) than either single assay. The changes of urinary pseudouridine and 1-methyladenosine reflected the disease status of patients in remission or in relapse and the effect of chemotherapy. These results suggest that urinary pseudouridine and 1-methyladenosine might be clinically useful as complementary markers to the monitoring of the disease status of patients with leukemia and lymphoma by hematological examination.
引用
收藏
页码:181 / 189
页数:9
相关论文
共 26 条
[1]   TRANSFER-RNA MODIFICATION [J].
BJORK, GR ;
ERICSON, JU ;
GUSTAFSSON, CED ;
HAGERVALL, TG ;
JONSSON, YH ;
WIKSTROM, PM .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :263-287
[2]   URINARY NUCLEIC-ACID BREAKDOWN PRODUCTS AS MARKERS FOR TROPHOBLASTIC DISEASES [J].
BOREK, E ;
SHARMA, OK ;
BREWER, JI .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1983, 146 (08) :906-910
[3]  
BOREK E, 1984, TUMOUR BIOL, V5, P1
[4]  
BOREK E, 1977, CANCER RES, V37, P3362
[5]  
Borek E, 1972, Adv Cancer Res, V15, P163, DOI 10.1016/S0065-230X(08)60374-7
[6]  
BOREK E, 1983, RECENT RES CANCER, V84, P301
[7]  
FISCHBEIN A, 1983, CANCER RES, V43, P2971
[8]  
GEHRKE CW, 1979, CANCER RES, V39, P1150
[9]  
HELDMAN DA, 1983, BLOOD, V61, P291
[10]  
HELDMAN DA, 1983, J NATL CANCER I, V71, P269